Opus Genetics, Inc. (IRD) stock
IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30460% above fair value
$3.98−0.08 (-1.97%)
Close on Nov 13, 2026Market cap $331.12MP/E –Yield –
Opus Genetics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Opus Genetics's price to book ratio was 23.3× on Apr 30, 2026, against 4.5× a year earlier. Over the last 5 years it ranged from 0.8× to 25.0×, with a median of 2.8×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Apr 30, 2026 | 23.3× | +1.5 |
| 2025 | Dec 31, 2025 | 21.7× | +20.8 |
| 2024 | Dec 31, 2024 | 0.9× | −0.4 |
| 2023 | Dec 29, 2023 | 1.4× | −4.8 |
| 2022 | Dec 30, 2022 | 6.2× | +3.0 |
| 2021 | Dec 31, 2021 | 3.1× | +0.3 |
| 2020 | Jan 31, 2020 | 2.8× | +0.2 |
| 2019 | Dec 31, 2019 | 2.6× | −15.8 |
| 2018 | Dec 31, 2018 | 18.4× | +3.2 |
| 2017 | Dec 29, 2017 | 15.2× | +7.5 |
| 2016 | Dec 30, 2016 | 7.7× | −7.0 |
| 2015 | Dec 31, 2015 | 14.7× | −2.8 |
| 2014 | Dec 31, 2014 | 17.5× | −10.4 |
| 2013 | Dec 31, 2013 | 27.8× | +2.9 |
| 2012 | Dec 31, 2012 | 25.0× | +10.7 |
| 2011 | Dec 30, 2011 | 14.2× | – |
See a number that looks wrong?